A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(27 sites)
China
The Second Hospital Of Anhui Medical University, Hefei, Anhui Beijing Cancer Hospital, Beijing, Beijing Municipality Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing Municipality Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality The Second Affiliated Hospital Of Chongqing Medical University, Chongqing, Chongqing Municipality Last updated December 2025